N4 Pharma PLC on Tuesday announced successful in vitro testing of Nuvec when loaded with two small interfering siRNA probes.
N4 is a Derbyshire, England-based pharmaceutical company focused on the development of a novel silica nanoparticle delivery system, known as Nuvec, for vaccines and therapeutics for licensing to pharmaceutical and biotech partners.
siRNA can prevent cells from communicating, and could potentially prevent cancer cells from replicating.
After announcing in September that it would focus on developing multiple loaded siRNA on Nuvec, N4 said it has now completed in vitro testing, which showed both probes were able to ‘significantly silence’ their respective targets.
N4 can now begin further work with EGFR and BCl-2 in a PC9 lung cancer model.
‘Achieving the initial successful testing of Nuvec with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking,’ added Chief Executive Officer Nigel Theobald.
N4 shares were trading 10% higher at 2.20 pence each in London on Tuesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
